Apelin and its receptor APJ in cardiovascular diseases

Clinica Chimica Acta

Volumn 428, Issue , 2014, Pages 1-8

  Yu, Xiao Hua ^a   Tang, Zhi Bin ^b   Liu, Li Jing ^c   Qian, Hong ^c   Tang, Shi Lin ^b   Zhang, Da Wei ^d   Tian, Guo Ping ^a,e   Tang, Chao Ke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^c HUAIHUA MEDICAL COLLEGE   (China)

^d UNIVERSITY OF ALBERTA   (Canada)

^e THE SECOND AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apelin; APJ; Atherosclerosis; CAD; Heart failure; Hypertension

Indexed keywords

ABC TRANSPORTER A1; ADIPOCYTOKINE; APELIN; APELIN RECEPTOR; BONE MORPHOGENETIC PROTEIN; CANNABINOID RECEPTOR; CYCLIC AMP; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; ORPHAN NUCLEAR RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; APLN PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIUM; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; PATHOGENESIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; VASODILATATION; METABOLISM;

CARDIOVASCULAR DISEASES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84887538188     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.09.001     Document Type: Review

References (98)

1. Cheng B., Chen J., Bai B., Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides 2012, 37:171-173.
2. Lv D., Li H., Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2013, 45:527-533.
3. Galanth C., Hus-Citharel A., Li B., Llorens-Cortes C. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 2012, 18:789-798.
4. Tycinska A.M., Lisowska A., Musial W.J., Sobkowicz B. Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta 2012, 413:406-410.
5. Barnes G., Japp A.G., Newby D.E. Translational promise of the apelin-APJ system. Heart 2010, 96:1011-1016.
6. Kalea A.Z., Batlle D. Apelin and ACE2 in cardiovascular disease. Curr Opin Investig Drugs 2010, 11:273-282.
7. Geurts L., Lazarevic V., Derrien M., et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2011, 2:149.
8. Geiger K., Muendlein A., Stark N., et al. Hypoxia induces apelin expression in human adipocytes. Horm Metab Res 2011, 43:380-385.
9. Yamagata K., Tagawa C., Matsufuji H., Chino M. Dietary apigenin regulates high glucose and hypoxic reoxygenation-induced reductions in apelin expression in human endothelial cells. J Nutr Biochem 2012, 23:929-936.
10. Melgar-Lesmes P., Pauta M., Reichenbach V., et al. Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut 2011, 60:1404-1411.
11. Than A., Tee W.T., Chen P. Apelin secretion and expression of apelin receptors in 3T3-L1 adipocytes are differentially regulated by angiotensin type 1 and type 2 receptors. Mol Cell Endocrinol 2012, 351:296-305.
12. Poirier O., Ciumas M., Eyries M., Montagne K., Nadaud S., Soubrier F. Inhibition of apelin expression by BMP signaling in endothelial cells. Am J Physiol Cell Physiol 2012, 303:C1139-C1145.
13. Krist J., Wieder K., Kloting N., et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts 2013, 6:57-69.
14. Lim R., Barker G., Riley C., Lappas M. Apelin is decreased with human preterm and term labor and regulates prolabor mediators in human primary amnion cells. Reprod Sci 2013, 20:957-967.
15. Li L., Xie F., Zhang Z., et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin (Shanghai) 2013, [Epub ahead of print].
16. Lu Y., Zhu X., Liang G.X., et al. Apelin-APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-kappaB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids 2012, 43:2125-2136.
17. Kasai A., Ishimaru Y., Higashino K., et al. Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis. Angiogenesis 2013, 16:723-734.
18. Chu J., Zhang H., Huang X., et al. Apelin ameliorates TNF-alpha-induced reduction of glycogen synthesis in the hepatocytes through G protein-coupled receptor APJ. PLoS One 2013, 8:e57231.
19. Kang Y., Kim J., Anderson J.P., et al. Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 2013, 113:22-31.
20. Than A., Cheng Y., Foh L.C., et al. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol Cell Endocrinol 2012, 362:227-241.
21. Yasuzaki H., Yoshida S., Hashimoto T., et al. Involvement of the apelin receptor APJ in Fas-induced liver injury. Liver Int 2013, 33:118-126.
22. Cui R.R., Mao D.A., Yi L., et al. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids 2010, 39:1193-1200.
23. Lv S.Y., Yang Y.J., Chen Q. Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides 2013, 44:87-92.
24. Tatemoto K., Takayama K., Zou M.X., et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001, 99:87-92.
25. Ishida J., Hashimoto T., Hashimoto Y., et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004, 279:26274-26279.
26. Maguire J.J., Kleinz M.J., Pitkin S.L., Davenport A.P. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009, 54:598-604.
27. Tempel D., de Boer M., van Deel E.D., et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circ Res 2012, 111:585-598.
28. Cheng X., Cheng X.S., Pang C.C. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003, 470:171-175.
29. De Mota N., Reaux-Le Goazigo A., El Messari S., et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004, 101:10464-10469.
30. Ashley E.A., Powers J., Chen M., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005, 65:73-82.
31. Szokodi I., Tavi P., Foldes G., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002, 91:434-440.
32. Charo D.N., Ho M., Fajardo G., et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 2009, 297:H1904-H1913.
33. Yu X.H., Fu Y.C., Zhang D.W., Yin K., Tang C.K. Foam cells in atherosclerosis. Clin Chim Acta 2013, 424C:245-252.
34. Liu X.Y., Lu Q., Ouyang X.P., et al. Apelin-13 increases expression of ATP-binding cassette transporter A1 via activating protein kinase C alpha signaling in THP-1 macrophage-derived foam cells. Atherosclerosis 2013, 226:398-407.
35. Rittig K., Hildebrandt U., Thamer C., et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes 2011, 119:358-361.
36. Kadoglou N.P., Sailer N., Moumtzouoglou A., et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability. Eur J Clin Invest 2012, 42:1278-1286.
37. Kadoglou N.P., Fotiadis G., Kapelouzou A., Kostakis A., Liapis C.D., Vrabas I.S. The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with Type 2 diabetes. Diabet Med 2013, 30:e41-e50.
38. Chun H.J., Ali Z.A., Kojima Y., et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008, 118:3343-3354.
39. Hashimoto T., Kihara M., Imai N., et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007, 171:1705-1712.
40. Pitkin S.L., Maguire J.J., Kuc R.E., Davenport A.P. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010, 160:1785-1795.
41. Peltonen T., Napankangas J., Vuolteenaho O., et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis 2009, 18:644-652.
42. Jin W., Su X., Xu M., et al. Interactive association of five candidate polymorphisms in apelin/APJ pathway with coronary artery disease among Chinese hypertensive patients. PLoS One 2012, 7:e51123.
43. Weir R.A., Chong K.S., Dalzell J.R., et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 2009, 11:551-558.
44. Ye J., Ni P., Kang L., Xu B. Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction. J Biomed Res 2012, 26:400-409.
45. Tycinska A.M., Sobkowicz B., Mroczko B., et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 2010, 411:2014-2018.
46. Kuklinska A.M., Sobkowicz B., Sawicki R., et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010, 25:363-367.
47. Kadoglou N.P., Lampropoulos S., Kapelouzou A., et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease - KOZANI STUDY. Transl Res 2010, 155:238-246.
48. Li Z., Bai Y., Hu J. Reduced apelin levels in stable angina. Intern Med 2008, 47:1951-1955.
49. Azizi Y., Faghihi M., Imani A., Roghani M., Nazari A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013, 46:76-82.
50. Li L., Zeng H., Chen J.X. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol 2012, 303:H605-H618.
51. Pisarenko O.I., Serebryakova L.I., Pelogeykina Y.A., et al. In vivo reduction of reperfusion injury to the heart with apelin-12 peptide in rats. Bull Exp Biol Med 2011, 152:79-82.
52. Zeng H., Li L., Chen J.X. Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One 2012, 7:e35905.
53. Iwanaga Y., Kihara Y., Takenaka H., Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006, 41:798-806.
54. Kuba K., Zhang L., Imai Y., et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007, 101:e32-e42.
55. Scimia M.C., Hurtado C., Ray S., et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012, 488:394-398.
56. Foldes G., Horkay F., Szokodi I., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003, 308:480-485.
57. Chandrasekaran B., Kalra P.R., Donovan J., Hooper J., Clague J.R., McDonagh T.A. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail 2010, 16:556-561.
58. Chong K.S., Gardner R.S., Morton J.J., Ashley E.A., McDonagh T.A. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006, 8:355-360.
59. Gao L.R., Xu R.Y., Zhang N.K., et al. Increased apelin following bone marrow mononuclear cell transplantation contributes to the improvement of cardiac function in patients with severe heart failure. Cell Transplant 2009, 18:1311-1318.
60. Berry M.F., Pirolli T.J., Jayasankar V., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004, 110:II187-II193.
61. Dai L., Smith P.M., Kuksis M., Ferguson A.V. Apelin acts in the subfornical organ to influence neuronal excitability and cardiovascular function. J Physiol 2013, 591:3421-3432.
62. Pchejetski D., Foussal C., Alfarano C., et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 2012, 33:2360-2369.
63. Japp A.G., Cruden N.L., Barnes G., et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010, 121:1818-1827.
64. Fukushima H., Kobayashi N., Takeshima H., Koguchi W., Ishimitsu T. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 2010, 55:83-88.
65. Koguchi W., Kobayashi N., Takeshima H., Ishikawa M., Sugiyama F., Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012, 76:137-144.
66. Barnes G.D., Alam S., Carter G., et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail 2013, 6:482-491.
67. Papadopoulos D.P., Mourouzis I., Faselis C., et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013, 15:333-336.
68. Przewlocka-Kosmala M., Kotwica T., Mysiak A., Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011, 29:971-979.
69. Najafipour H., Soltani Hekmat A., Nekooian A.A., Esmaeili-Mahani S. Apelin receptor expression in ischemic and non-ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept 2012, 178:43-50.
70. Furuya M., Okuda M., Usui H., et al. Expression of angiotensin II receptor-like 1 in the placentas of pregnancy-induced hypertension. Int J Gynecol Pathol 2012, 31:227-235.
71. Falcone C., Bozzini S., Schirinzi S., et al. APJ polymorphisms in coronary artery disease patients with and without hypertension. Mol Med Rep 2012, 5:321-325.
72. Akcilar R., Turgut S., Caner V., et al. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens 2013, [Epub ahead of print].
73. Kursunluoglu-Akcilar R., Kilic-Toprak E., Kilic-Erkek O., Turgut S., Bor-Kucukatay M. Apelin-induced hemorheological alterations in DOCA-salt hypertensive rats. Clin Hemorheol Microcirc 2013, [Epub ahead of print].
74. Jia Y.X., Lu Z.F., Zhang J., et al. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007, 28:2023-2029.
75. Zhang Q., Yao F., Raizada M.K., O'Rourke S.T., Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res 2009, 104:1421-1428.
76. Nagano K., Ishida J., Unno M., Matsukura T., Fukamizu A. Apelin elevates blood pressure in ICR mice with LNAME induced endothelial dysfunction. Mol Med Rep 2013, 7:1371-1375.
77. Chandra S.M., Razavi H., Kim J., et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011, 31:814-820.
78. Alastalo T.P., Li M., Perez Vde J., et al. Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 2011, 121:3735-3746.
79. Falcao-Pires I., Goncalves N., Henriques-Coelho T., Moreira-Goncalves D., Roncon-Albuquerque R., Leite-Moreira A.F. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009, 296:H2007-H2014.
80. Kim J., Kang Y., Kojima Y., et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013, 19:74-82.
81. Smith C.C., Yellon D.M. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011, 129:206-219.
82. Kleinz M.J., Baxter G.F. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008, 146:271-277.
83. Tao J., Zhu W., Li Y., et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol 2011, 301:H1471-H1486.
84. Zeng X.J., Zhang L.K., Wang H.X., Lu L.Q., Ma L.Q., Tang C.S. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009, 30:1144-1152.
85. Simpkin J.C., Yellon D.M., Davidson S.M., Lim S.Y., Wynne A.M., Smith C.C. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 2007, 102:518-528.
86. Farkasfalvi K., Stagg M.A., Coppen S.R., et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007, 357:889-895.
87. Ellinor P.T., Low A.F., Macrae C.A. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006, 27:222-226.
88. Falcone C., Buzzi M.P., D'Angelo A., et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 2010, 23:917-925.
89. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013, 34:1475-1480.
90. Kallergis E.M., Manios E.G., Kanoupakis E.M., et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol 2010, 105:90-94.
91. Wang M., Gupta R.C., Rastogi S., et al. Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail 2013, 19:509-516.
92. Kadoglou N.P., Sailer N., Kapelouzou A., et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol 2012, 49:269-276.
93. Wang I.N., Wang X., Ge X., et al. Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. PLoS One 2012, 7:e38328.
94. Iturrioz X., Alvear-Perez R., De Mota N., et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 2010, 24:1506-1517.
95. Wang W., McKinnie S.M., Patel V.B., et al. Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. J Am Heart Assoc 2013, 2:e000249.
96. Pisarenko O.I., Pelogeykina Y.A., Bespalova Zh D., et al. Limitation of myocardial infarction by a structural analog of the peptide apelin-12. Dokl Biol Sci 2012, 443:65-67.
97. Jia Z.Q., Hou L., Leger A., et al. Cardiovascular effects of a PEGylated apelin. Peptides 2012, 38:181-188.
98. Lambrecht N.W., Yakubov I., Zer C., Sachs G. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics 2006, 25:153-165.